MARC details
000 -LEADER |
fixed length control field |
04437nam a22004695i 4500 |
001 - CONTROL NUMBER |
control field |
978-3-031-24575-6 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
DE-He213 |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20240729135210.0 |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
fixed length control field |
cr nn 008mamaa |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
230303s2023 sz | s |||| 0|eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
9783031245756 |
-- |
978-3-031-24575-6 |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MJD |
Source |
bicssc |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MED010000 |
Source |
bisacsh |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MJD |
Source |
thema |
245 10 - TITLE STATEMENT |
Title |
Lipoprotein(a) |
250 ## - EDITION |
Edition statement |
1st ed. 2023. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
Place of production, publication, distribution, manufacture |
Cham : |
Name of producer, publisher, distributor, manufacturer |
Springer International Publishing : |
-- |
Imprint: Humana, |
Date of production, publication, distribution, manufacture, or copyright notice |
2023. |
300 ## - PHYSICAL DESCRIPTION |
Physical description |
XVII, 443 p. 92 illus., 76 illus. in color. |
Other physical details |
online resource. |
336 ## - CONTENT TYPE |
Content type term |
text |
Content type code |
txt |
Source |
rdacontent |
337 ## - MEDIA TYPE |
Media type term |
computer |
Media type code |
c |
Source |
rdamedia |
338 ## - CARRIER TYPE |
Carrier type term |
online resource |
Carrier type code |
cr |
Source |
rdacarrier |
490 1# - SERIES TITLE |
Series statement |
Contemporary Cardiology, |
International Standard Serial Number |
2196-8977 |
505 0# - CONTENTS |
Contents |
60 years of Lp(a) research-From Ouchterlonys double diffusion to a significant risk factor for CHD -- Lp(a) structure and composition -- Genetics of Lipoprotein(a) -- Lp(a) metabolism -- Contemporary aspects of Lp(a) metabolism and therapies based on tracer kinetic methods -- Role of Proprotein Convertase Subtilisin Kexin type 9 in Lipoprotein(a) Metabolism -- The Role of Cell Surface Receptors in Lp(a) Metabolism -- Physiological Roles And Functions Of Lipoprotein(a) -- The role of Lp(a) in Atherosclerosis: An overview -- Role of macrophages in Lp(a) pathophysiology -- Thrombosis, Inflammation and Lipoprotein(a): Clinical Implications -- The role of the kidney in Lp(a) physiology and pathophysiology -- Lp(a) as a cardiovascular risk factor -- Lp(a) and aortic valve stenosis, stroke, and other non-coronary cardiovascular diseases -- Lp(a) in cardiovascular disease: Evidence from Large Epidemiological Studies -- Lipoprotein(A) And Immunity -- When to measure Lp(a) -- Measurement of Lipoprotein (a) in the Clinical Laboratory -- Standardization of analytical methods for the measurement of Lipoprotein(a): bridging past and future initiatives -- Establishing an SI-traceable Reference Measurement System for Lp(a), based on Quantitative Protein Mass Spectrometry and Molar Units -- Compounds that impact Lp(a) concentrations -- Antisense oligonucleotide therapy to treat elevated lipoprotein(a) -- Lipoprotein apheresis for reduction of Lipoprotein(a) -- Elevated Lp(a) - Why Should I Test For It, If I Cannot Treat It? A Patient's Perspective -- Burning unanswered questions Therapy. |
520 ## - ABSTRACT |
Abstract |
Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for cardiovascular vascular disease. Data from case control, epigenetic and mendelian randomization studies indicate that people with elevated Lp(a) have a two-fold to four-fold increased risk of cardiovascular events compared to people with low Lp(a) levels. Despite this risk, awareness of Lp(a) is still very low among health care providers. Even cardiologists often overlook Lp(a), in part because Lp(a) is not as well-understood as other risk factors and treatment options are still very limited. This book offers an authoritative and comprehensive overview of Lipoprotein(a). It provides an in-depth review of all aspects of Lp(a), from pathophysiology to metabolism. Chapters offer the reader a contemporary view of the important roles of Lp(a) as a risk factor for cardiovascular disease. In addition, this volume discusses the clinical implications of elevated Lp(a) and current and future therapies. Lipoprotein(a) is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention. |
650 #0 - SUBJECT HEADINGS |
Subject term |
Cardiology. |
650 #0 - SUBJECT HEADINGS |
Subject term |
Internal medicine. |
9 (RLIN) |
6654 |
650 14 - SUBJECT HEADINGS |
Subject term |
Cardiology. |
650 24 - SUBJECT HEADINGS |
Subject term |
Internal Medicine. |
9 (RLIN) |
6654 |
700 1# - ADDED PERSONAL NAME |
Added personal author |
Kostner, Karam. |
Relator term |
editor. |
700 1# - ADDED PERSONAL NAME |
Added personal author |
Kostner, Gerhard M. |
Relator term |
editor. |
700 1# - ADDED PERSONAL NAME |
Added personal author |
Toth, Peter P. |
Relator term |
editor. |
710 2# - ADDED CORPORATE NAME |
Added corporate author |
SpringerLink (Online service) |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
Uniform title |
Contemporary Cardiology, |
International Standard Serial Number |
2196-8977 |
856 ## - ONLINE RESOURCE |
Uniform Resource Identifier |
<a href="#gotoholdings">#gotoholdings</a> |
Link text |
Access resource |
245 ## - TITLE STATEMENT |
Medium |
[E-Book] |
347 ## - DIGITAL FILE CHARACTERISTICS |
File type |
text file |
Encoding format |
PDF |
Source |
rda |
912 ## - |
-- |
ZDB-2-SME |
912 ## - |
-- |
ZDB-2-SXM |